![]() With a smart 5 years tangible implementation plan, marketing agreements within existing regional collaborations and with a strong political will, an African government alone or together with an investor could convince global vaccine stakeholders and investors to support. Attractiveness for the African market is deemed to be high when targeting diseases almost exclusively for Africa (e.g., malaria or invasive non-typhoidal salmonella). A respective antigen production facility is estimated to cost USD 25 Million, an affordable dimension for investors or interested African governments. A feasible solution could be a small production facility that would use technologies with high yield at low costs of goods to cover the regional needs. The diverse political ambitions among African governments make it difficult to predict and access the market, a prerequisite for competitive production. The global vaccine stakeholders showed less preference in investment for vaccine production establishment in Africa. ![]() The common regulatory functionality gap was the quality control laboratories to test vaccine lots before regulatory release. We saw that, governments in Africa, show interest in vaccine production establishments but only with external support for investment. We also developed business plan scenarios including facility costs calculations and a possible investment plan based on expert opinions and publicly available information from pertinent sources. In-depth interviews with experts in manufacturing capacity implementation and regulatory capacity building in Africa complemented the study. The investigation was based on a literature review and supplemented by online questionnaires directed to global vaccine stakeholders, African governments and regulatory authorities. This study aimed to investigate how investment for vaccine production in Africa could be triggered and in which way it could be affordable to most African governments or investors. Conversely, Africa with its high population and economy growth is an increasing potential market for vaccines. ![]() GAVI has significantly helped introduction of new vaccines in Africa but its sustainability is questionable, and new vaccines introduction post-graduation is rare.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |